Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: September 2014

Chapter 22 - Secondary prevention

from Section 4: - Therapeutic strategies and neurorehabilitation


1. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32:2559–66.
2. Wolf PA, Cobb JL, D’Agostino RB. Epidemiology of stroke. In Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis and Management. New York: Churchill Livingstone; 1992: 3–27.
3. Hill MD, Yiannakoulias N, Jeerakathil T, et al. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62:2015–20.
4. Lovett J, Coull A, Rothwell P. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62:569–73.
5. Weimar C, Roth MP, Zillessen G, et al. Complications following acute ischemic stroke. Eur Neurol 2002; 48:133–40.
6. Coutts SB, Eliasziw M, Hill MD, et al. An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. Int J Stroke 2008; 3(1):3–10.
7. Weimar C, Goertler M, Rother J, et al. Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA): a prospective cross sectional study in 85 German stroke units. J Neurol 2007; 254(11):1562–8.
8. Giles MF, Rothwell PM. Risk of stroke early after transient ischemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6(12):1063–72.
9. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370(9596):1432–42.
10. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15):1547–59.
11. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34:2741–8.
12. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355:1575–81.
13. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358:1033–41.
14. Schrader J, Lüders S, Kulschewski A, et al.; The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699–703.
15. Yusuf S, Diener HC, Sacco RL, et al. Randomized trial of telmisartan therapy to prevent recurrent strokes and major vascular events among 20,332 individuals with recent stroke. N Engl J Med 2008; 359:1225–37.
16. The SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382(9891): 507–15. Erratum in Lancet 2013; 382(9891): 506.
17. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007; 24(2–3):170–82.
18. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35(12):2902–9.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44(3):720–32.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7–22.
21. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757–67.
22. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549–59.
23. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37(10):2640–3.
24. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69(9):904–10.
25. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38(3):865–73.
26. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545–59.
27. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24):2560–72.
28. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291(5):565–75.
29. Lonn E, Yusu FS, Arnold MJ, et al.; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567–77.
30. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345:1243–9.
31. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81–106.
32. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 524:71–86.
33. Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol 2006; 147(Suppl 1):S241–51.
34. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 65:255.
35. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353(22):2373–83.
36. Topol E, Easton D, Harrington R, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108:16–23.
37. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502.
38. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) CAPRIE steering committee. Lancet 1996; 348:1329–39.
39. Diener H, Bogousslavsky J, Brass L, et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischemic stroke or transient ischemic attack: the MATCH trial results. Lancet 2004; 364:331–4.
40. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16):1706–17.
41. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49(19):1982–8.
42. Diener HC, Cuhna L, Forbes C, et al.; European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1–13.
43. Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55:162–3.
44. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665–73.
45. Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens and telmisartan vs. placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. Cerebrovasc Dis 2007; 23:368–80.
46. Diener HC, Ringleb PA, Savi P. Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother 2005; 6:755–64.
47. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005; 1:19–26.
48. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353:227–31.
49. The SPS3 Study Group. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367:817–25.
50. Wang Y, Johnston SC; CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010; 160(3):380–6.
51. Wang Y, Johnston SC; CHANCE Investigators. Clopidogrel and aspirin versus aspirin alone for the treatment of high-risk patients with acute non-disabling cerebrovascular event (CHANCE): a randomized, double-blind, placebo-controlled multicenter trial. Presented at: The International Stroke Conference; 2013; February 6–8; Honolulu, Hawaii.
52.University of California, San Francisco. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jun 22]. Available from: NLM Identifier: NCT00991029.
53. EAFT Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342:1255–62.
54. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Stroke 2004; 35:1782–3.
55. Hart R, Pearce L, Miller V, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10:39–43.
56. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26(22):2422–34.
57. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8(9):651–745.
58. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115(21):2689–96.
59. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903–12.
60. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51.
61. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–91.
62. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–92.
63. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806–17.
64. Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366:1859–69.
65. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59:17–20.
66. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007; 357:2262–8.
67. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366:991–9.
68. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368:1092–100.
69. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368:1083–91.
70. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42:857–65.
71. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444–51.
72. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6(2):115–24.
73. Algra A, De Schryver E, van Gijn J, Kappelle L, Koudstaal P. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006; 3:CD001342.
74. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291(5):576–84.
75. Beletsky V, Nadareishvili Z, Lynch J, et al. Cervical arterial dissection. Time for a therapeutic trial? Stroke 2003; 34:2856–60.
76. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Stroke 2004; 35(2):613–14.
77. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007; 38(9):2605–11.
78. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339:1415–25.
79. European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379–87.
80. European Carotid Surgery Trialists’ Collaborative Group. MRC European carotid surgery trial: interim results for symptomatic patients with severe carotid stenosis and with mild carotid stenosis. Lancet 1991; 337:1235–43.
81. Ferguson GG, Eliasziw M, Barr HWK, et al. The North American symptomatic carotid endarterectomy trial: surgical result in 1415 patients. Stroke 1999; 30:1751–8.
82. Rothwell PM, Warlow CP, on behalf of the European Carotid Surgery Trialists’ Collaborative Group. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 1999; 353:2105–10.
83. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361:107–16.
84. Rothwell P, Eliasziw M, Gutnikov S, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915–24.
85. Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy – an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65(6):794–801.
86. Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368(9543):1239–47.
87. Stingele R, Berger J, Alfke K, et al. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol 2008; 7(3):216–22.
88. Mas JL, Chatellier G, Beyssen B, et al.; EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355:1660–71.
89. Kern R, Ringleb PA, Hacke W, Mas JL, Hennerici MG. Stenting for carotid artery stenosis. Nat Clin Pract Neurol 2007; 3(4):212–20.
90. Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11–23.
91. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352(13):1305–16.
92. Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113(4):555–63.
93. Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology 2008; 70(17):1518–24.
94. Jiang WJ, Xu XT, Du B, et al. Comparison of elective stenting of severe vs. moderate intracranial atherosclerotic stenosis. Neurology 2007; 68(6):420–6.
95. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365:993–1003.